In particular, we are focused on hematologic disorders, cancer and rare immune diseases. We see great opportunity to help patients who have diseases where few or no approved treatment options exist.
Fostamatinib is also currently being studied in a Phase 3 open-label extension study (NCT04138927) for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA) and an NIH/NHLBI-sponsored Phase 3 clinical trial (NCT04924660) for the treatment of COVID-19 in hospitalized patients.
Our other clinical programs include an interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program. Rigel is collaborating with Eli Lilly to develop Rigel’s RIPK1 inhibitors in immunological and neurodegenerative diseases.
In addition, Rigel has an extensive portfolio of investigational agents being developed with our other partners. These products are focused on the inhibition of select signaling pathways, including Axl tyrosine kinase (AXL) and murine double minute 2 (MDM2). Through strategic partnerships and collaborations, we are able to take advantage of additional experience and resources, while benefiting from the potential success of these future products, both through milestone payments and royalties.* Please see the TAVALISSE Full Prescribing Information